Longitudinal association between polypharmacy and development of pruritus: a Nationwide Cohort Study in a Japanese Population. (23rd June 2021)

• Record Type: Journal Article
• Authors: Kogame, T.; Kamitani, T.; Yamazaki, H.; Ogawa, Y.; Fukuhara, S.; Kabashima, K.; Yamamoto, Y.
• Is Part Of: Journal of the European Academy of Dermatology and Venereology. Volume 35:Number 10(2021)
• Page Start: 2059
• Page End: 2066
• Publication Date: 2021-06-23
• Subjects: Dermatology -- Periodicals; Sexually transmitted diseases -- Periodicals; 616.5
• DOI: 10.1111/jdv.17443
• Languages: English
• ISSNs: 0926-9959

Abstract

Abstract: Background: Although polypharmacy is known to cause side‐effects due to drug–drug interactions, dermatological symptoms triggered by polypharmacy are not fully addressed. Objective: To investigate whether polypharmacy is associated with the risk of pruritus. Method: A cohort study was performed to examine cross‐sectional and longitudinal relationships between polypharmacy and pruritus in a general population. Data were collected from the Norm Study conducted in 2016 and 2017, which is a nationwide survey based on a self‐administered questionnaire with Japanese representative participants aged 16–84 years. Presence of polypharmacy which was defined as concurrent use of ≥5 prescribed drugs. Primary outcomes were the presence of severe pruritus at baseline for the cross‐sectional analysis and the development of severe pruritus after one year for the longitudinal analysis. Multivariable modified Poisson regression analyses were performed to estimate risk ratios (RRs) and 95% confidence intervals (95%CIs) with adjustment for potential confounders (age, gender, smoking habits, drinking habits, depressive symptoms, moderate activities based on IPAQ score and presence of 11 comorbid conditions including skin disease). Results: The study included 3126 participants (mean age, 48.7 years); nearly half (49.8%) were male. In all, 332 participants (10.3%) had polypharmacy in the cross‐sectional analysis. Participants with polypharmacy were more likely to present with severe pruritus at baseline than those who were not using drugs (adjusted RR = 1.52 [95%CI 1.15–2.01, P = 0.003]). The longitudinal analysis ( n = 1803) was limited to those without severe pruritus at baseline; participants with polypharmacy at baseline were more likely to develop severe pruritus after a one‐year follow‐up period than those not using drugs (adjusted RR = 1.46 [95%CI 1.14–1.87, P = 0.002]). Conclusion: Polypharmacy was associated with the presence of pruritus at baseline and may predict the future risk of developing pruritus.